HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies.

Lung cancer stands as the first cause of death by cancer in the world. Despite the improvement in patients' outcomes in the past decades through the development of personalized medicine approaches, a substantial portion of patients remains ineligible for targeted therapies due to the lack of a "druggable" molecular target. HER2, a receptor tyrosine kinase member of the EGFR/ErbB family, is known to show oncogenic properties.

Transcriptomic FHIT/pHER2 signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.

Introduction: In recent decades, the development of immunotherapy and targeted therapies has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients. Despite these impressive clinical benefits, new biomarkers are needed for an accurate stratification of NSCLC patients and a more personalized management. We recently showed that the tumor suppressor fragile histidine triad (FHIT), frequently lost in NSCLC, controls HER2 receptor activity in lung tumor cells and that tumor cells from NSCLC patients harboring a FHIT/pHER2 phenotype are sensitive to anti-HER2 drugs.

Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2).

S100A1 is a Ca2+-binding protein of the EF-hand type that belongs to the S100 protein family. It is specifically expressed in the myocardium at high levels and is considered to be an important regulator of cardiac contractility. Because the S100A1 protein is released into the extracellular space during ischemic myocardial injury, we examined the cardioprotective potential of the extracellular S100A1 protein on ventricular cardiomyocytes in vitro.

Beta versus gamma dosimetry close to Ir-192 brachytherapy sources.

The relative importance of the dose rate component owing to the beta spectrum emitted by 192Ir brachytherapy sources at the short radial distances of interest in intravascular and endobronchial applications is investigated. Separate dosimetric calculations, using Monte Carlo simulations, were performed for the gamma and beta dose rate components of an 192Ir ideal point source as well as real 192Ir source designs used in clinical practice including wire and seed sources and both Nucletron and Varian, old and new, high dose rate (HDR) source designs. A significant dose rate enhancement due to the beta spectrum emitted by 192Ir, greater than 50% for radial distances r<2 mm, was observed for an ideal point source.